Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease
- 31 July 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 191 (1) , 93-105
- https://doi.org/10.1016/s1072-7515(00)00305-7
Abstract
No abstract availableThis publication has 52 references indexed in Scilit:
- Antisense-mediated Repression of DNA Topoisomerase II Expression Leads To an Impairment of HIV-1 Replicative CycleJournal of Molecular Biology, 1999
- FomivirsenDrugs, 1999
- Ex vivo gene therapy prevents chronic graft vascular disease in cardiac allograftsThe Journal of Thoracic and Cardiovascular Surgery, 1998
- BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 1997
- Towards Genomic Drug Therapy with Antisense OligonucleotidesAnnals of Medicine, 1996
- The state of the art in antisense researchNature Medicine, 1995
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Re-Stenosis after Successful Coronary AngioplastyNew England Journal of Medicine, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985